GANX

Gain Therapeutics Stock Analysis

AI Rating

Neutral
  • Quality0/10
  • Growth↑ 5/10
  • Value↑ 5/10
Gain Therapeutics sales and earnings growth
GANX Growth
Neutral
  • Revenue Y/Y↓ 0.00%
  • EPS Y/Y↑ 31.46%
  • FCF Y/Y↓ 2.28%
Gain Therapeutics gross and profit margin trends
GANX Profitability
Low
  • Gross margin ↓ 0.00%
  • EPS margin↓ 0.00%
  • ROIC 5Y↑ 378.04%
Gain Therapeutics net debt vs free cash flow
GANX Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Gain Therapeutics stock volatility is in-line with the overall market. We give it a Great risk rating.

↗ More Biotechnology stocks